The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001401914 Tempo Pharmaceuticals Inc X Corporation

Name of Issuer Limited Partnership

Cerulean Pharma Inc.

Limited Liability Company

Jurisdiction of
Incorporation/OrganizationGeneral Partnership
Business TrustDELAWAREOther (Specify)

Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2005

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Cerulean Pharma Inc.

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

Cambridge MASSACHUSETTS 02139 617-551-9600

3. Related Persons

Last Name First Name Middle Name

Crane Alan

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Fetzer Oliver

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name Hall Steven E. **Street Address 1 Street Address 2** 840 Memorial Drive 5th Floor **State/Province/Country** ZIP/PostalCode City **MASSACHUSETTS** Cambridge 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name **Roberts** Bryan E. **Street Address 1 Street Address 2** 840 Memorial Drive 5th Floor City State/Province/Country ZIP/PostalCode Cambridge **MASSACHUSETTS** 02139 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name Middle Name** Sasisekharan Ram **Street Address 1** Street Address 2 840 Memorial Drive 5th Floor State/Province/Country ZIP/PostalCode City **MASSACHUSETTS** Cambridge 02139 **Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last NameFirst NameMiddle NameTepperRobertStreet Address 1Street Address 2840 Memorial Drive5th FloorCityState/Province/CountryZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Cambridge MASSACHUSETTS 02139

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

840 Memorial Drive

Last NameFirst NameMiddle NameDeMagistrisDavidP.

Street Address 1 Street Address 2

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

5th Floor

Cambridge Windows Circuit Service Country Coun

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name
Glucksmann Alexandra
Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Roberts Karen

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Ryan John

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

Silveri Jean

Street Address 1 Street Address 2

840 Memorial Drive 5th Floor

City State/Province/Country ZIP/PostalCode

Cambridge MASSACHUSETTS 02139

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing
Banking & Financial Services Biotechnology Restaurants
Commercial Banking Health Insurance Technology

Insurance Health Insurance Technology

Health Insurance Technology

Hospitals & Physicians Computers

Investing

Investment Banking

X Pharmaceuticals

Telecommunications

Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate

Airlines & Airports

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Other Travel

Business Services Residential Other

Energy Other Real Estate

Coal Mining

Energy Conservation
Environmental Services

Electric Utilities

5. Issuer Size

Revenue Range	OR		Aggregate Net Asset Value Range	
No Revenues		No Aggregate Ne	et Asset Value	
\$1 - \$1,000,000		\$1 - \$5,000,000		
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,	,000,000	
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50	0,000,000	
\$25,000,001 - \$100,000,000		\$50,000,001 - \$10	00,000,000	
Over \$100,000,000		Over \$100,000,00	00	
X Decline to Disclose		Decline to Disclo	ose	
Not Applicable		Not Applicable		
6. Federal Exemption(s) and l	Exclusion(s) Claim	ed (select all that a	apply)	
Rule 504(b)(1) (not (i), (ii)	or (iii))	Rule 505		
Rule 504 (b)(1)(i)		X Rule 506		
Rule 504 (b)(1)(ii)		Securities Act Section 4(5)		
Rule 504 (b)(1)(iii)		Investment Co	Company Act Section 3(c)	
		Section 3(c)(1	1) Section 3(c)(9)	
		Section 3(c)(2	2) Section 3(c)(10)	
		Section 3(c)(3	3) Section 3(c)(11)	
		Section 3(c)(4	4) Section 3(c)(12)	
		Section 3(c)(5	5) Section 3(c)(13)	
		Section 3(c)(6	6) Section 3(c)(14)	
		Section 3(c)(7	")	
7. Type of Filing				
X New Notice Date of First Amendment	Sale 2010-11-12	First Sale Yet to 0	Occur	
8. Duration of Offering				
Does the Issuer intend this of	fering to last more	than one year?	Yes X No	
9. Type(s) of Securities Offere	ed (select all that a	pply)		
X Equity			Pooled Investment Fund Interests	
Debt		.1. 0	Tenant-in-Common Securities	
Option, Warrant or Other I	Right to Acquire Ai	nother Security	Mineral Property Securities	

10. Business Combination Transaction

Other Right to Acquire Security

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Other (describe)

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

Security to be Acquired Upon Exercise of Option, Warrant or

12. Sales Compensation

Recipient CRD Number X None

(Associated) Broker or Dealer X None (Associated) Broker or Dealer CRD Number X None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

All States Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$23,999,989 USD or Indefinite

Total Amount Sold \$16,499,994 USD

Total Remaining to be Sold \$7,499,995 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

17

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment

Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Cerulean Pharma Inc.	/s/ Jean Silveri	Jean Silveri	Senior Vice President, General Counsel and Secretary	2010-11-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.